Abacavir, dolutegravir, lamivudine

Sold as Kavideza, Kavmyl, Dolab, Dometrib, Dobatrip, Dolvidin, Vuterar, Abacavir/dolutegravir/lamivudine hetero, Temilur, Damicava paed, Ablado paed, Domitidene, Telacadine, Abdovir, Dezkav

S4Read from the PI-PIL document and verified

Combination product

This product contains more than one active ingredient, so it has no single molecular structure.

Loading Wikipedia summary

Registration

Applicants: 9
Registrations: 15
Schedule source: SAHPRA documentation

Applicants and registrations

Applicant	Brands	Dosages	Registrations	Schedule	Leaflets
Viatris Healthcare (Pty) Ltd	Kavideza, Kavmyl, Dezkav	50 mg, 300 mg, 600 mg	530091, 530092.091, 600382	S4	PI PIL
Aurogen South Africa (Pty) Ltd	Dolab	tablets	530476	Not determined	None
Novagen Pharma (Pty) Ltd	Dometrib, Dolvidin	50 mg, 600 mg, 300 mg	530477.476, 540188	S4	PI PIL
Aurobindo Pharma (Pty) Ltd	Dobatrip	Not stated	530478.476	Not determined	None
Hetero Drugs South Africa (Pty) Ltd	Vuterar, Abacavir/dolutegravir/lamivudine hetero, Temilur	Not stated	550338, 550339.338, 550340.338	Not determined	None
Cipla Medpro (Pty) Ltd	Damicava paed, Ablado paed	60 mg, 5 mg & 30 mg	570509, 570510.509	S4	PI PIL
Laurus Generics SA (Pty) Ltd	Domitidene	Not stated	580051	Not determined	None
Pps Pharmaceuticals (Pty) Ltd	Telacadine	Not stated	580052.051	Not determined	None
Pharma Dynamics (Pty) Ltd	Abdovir	60 mg/5 mg/30 mg	590752	S4	PI PIL

Variants

Product	Strength and form	Registration	Status	Schedule	Leaflets
Kavideza EACH TABLET CONTAINS ABACAVIR 600,0 mg; DOLUTEGRAVIR 50,0 mg; LAMIVUDINE 300,0 mg	600 mg. 50 mg. 300 mgFilm-coated tablets	53009153/20.2.8/0091Approved 3 July 2025	Registered	S4	PI PIL
Kavmyl EACH TABLET CONTAINS ABACAVIR 600,0 mg DOLUTEGRAVIR 50,0 mg LAMIVUDINE 300,0 mg	600 mg. 50 mg. 300 mgFilm-coated tablets	530092.09153/20.2.8/0092.091Approved 3 July 2025	Registered	S4	PI PIL
Dolab tablets EACH TABLET CONTAINS ABACAVIR 600,0 mgDOLUTEGRAVIR SODIUM EQUIVALENT TO DOLUTEGRAVIR 50,0 mgLAMIVUDINE 300,0 mg	Tablets	53047653/20.2.8/0476	Registered	Not determined	None
Dometrib EACH TABLET CONTAINS ABACAVIR 600,0 mg DOLUTEGRAVIR SODIUM EQUIVALENT TO DOLUTEGRAVIR 50,0 mg LAMIVUDINE 300,0 mg	Not listed	530477.47653/20.2.8/0477.476	Registered	Not determined	None
Dobatrip EACH TABLET CONTAINS ABACAVIR 600,0 mg DOLUTEGRAVIR SODIUM EQUIVALENT TO DOLUTEGRAVIR 50,0 mg LAMIVUDINE 300,0 mg	Not listed	530478.47653/20.2.8/0478.476	Registered	Not determined	None
Dolvidin ABACAVIR; DOLUTEGRAVIR; LAMIVUDINE 600,0 mg, 50,0 mg , 300,0 mg	50 mg, 600 mg, 300 mgTablet	54018854/20.2.8/0188Approved 19 August 2024	Registered	S4	PI PIL
Vuterar EACH TABLET CONTAINS ABACAVIR 600,0 mg DOLUTEGRAVIR SODIUM EQUIVALENT TO DOLUTEGRAVIR 50,0 mg LAMIVUDINE 300,0 mg	Not listed	55033855/20.2.8/0338	Registered	Not determined	None
Abacavir/dolutegravir/lamivudine hetero EACH TABLET CONTAINS ABACAVIR 600,0 mg DOLUTEGRAVIR SODIUM EQUIVALENT TO DOLUTEGRAVIR 50,0 mg LAMIVUDINE 300,0 mg	Not listed	550339.33855/20.2.8/0339.338	Registered	Not determined	None
Temilur EACH TABLET CONTAINS ABACAVIR 600,0 mg DOLUTEGRAVIR SODIUM EQUIVALENT TO DOLUTEGRAVIR 50,0 mg LAMIVUDINE 300,0 mg	Not listed	550340.33855/20.2.8/340.338	Registered	Not determined	None
Damicava paed EACH TABLET CONTAINS ABACAVIR SULFATE 60,0 mg DOLUTEGRAVIR SODIUM 5,0 mg LAMIVUDINE 30,0 mg	60 mg, 5 mg & 30 mgDispersible tablet	57050957/20.2.8/0509Approved 14 May 2024	Registered	S4	PI PIL
Ablado paed EACH TABLET CONTAINS ABACAVIR SULFATE 60,0 mg DOLUTEGRAVIR SODIUM 5,0 mg LAMIVUDINE 30,0 mg	60 mg, 5 mg & 30 mgDispersible tablet	570510.50957/20.2.8/0510.509Approved 14 May 2024	Registered	S4	PI PIL
Domitidene EACH TABLET CONTAINS: ABACAVIR SULPHATE EQUIVALENT TO ABACAVIR 600,0 mg DOLUTEGRAVIR SODIUM EQUIVALENT TO DOLUTEGRAVIR 50,0 mg LAMIVUDINE 300,0 mg	Not listed	58005158/20.2.8/0051	Registered	Not determined	None
Telacadine EACH TABLET CONTAINS: ABACAVIR SULPHATE EQUIVALENT TO ABACAVIR 600,0 mg DOLUTEGRAVIR SODIUM EQUIVALENT TO DOLUTEGRAVIR 50,0 mg LAMIVUDINE 300,0 mg	Not listed	580052.05158/20.2.8/0052.051	Registered	Not determined	None
Abdovir EACH TABLET CONTAINS: ABACAVIR SULPHATE EQUIVALENT TO ABACAVIR 60,0 mg DOLUTEGRAVIR SODIUM EQUIVALENT TO DOLUTEGRAVIR 5,0 mg LAMIVUDINE 30,0 mg	60 mg/5 mg/30 mgOral suspension	59075259/20.2.8/0752Approved 30 June 2026	Registered	S4	PI PIL
Dezkav EACH TABLET CONTAINS: ABACAVIR 600,0 mg DOLUTEGRAVIR 50,0 mg LAMIVUDINE 300,0 mg	Not listed	60038260/20.2.8/0382	Registered	S4	None

Regulatory status

Where S4 sits on the scale

S0S1S2S3S4S5S6S7S8

Prescription-only medicine.

Schedule 4 covers most ordinary prescription medicines. You need a prescription from an authorised prescriber, such as a doctor or dentist, and a pharmacist dispenses it. Its price, name, pack size and strength can still be told to the public, as long as nothing links it to what it treats.

Schedule S4, read from the product's PI-PIL leaflet.

Who may supply: A pharmacist dispensing against a written or verbal prescription from an authorised prescriber; a veterinarian, who may also prescribe, compound or dispense it directly; a medical practitioner or dentist, who may prescribe it and may compound or dispense it directly only if licensed under section 22C(1)(a); manufacturers and wholesalers may supply people who may lawfully possess it; and, for animal treatment, a person practising a para-veterinary profession, on a veterinarian's written or verbal instruction.

Consolidated Schedules listings for Abacavir, dolutegravir, lamivudine

S4: Abacavir
Consolidated Schedules 06 July 2026, line 5118
S4: Dolutegravir
Consolidated Schedules 06 July 2026, line 6100
S4: Lamivudine
Consolidated Schedules 06 July 2026, line 6850

Pharmacological class: Antiviral agents. (class 20.2.8)

This is an informational summary of the Medicines and Related Substances Act 101 of 1965 and its 2017 General Regulations. It is not medical advice and not legal advice. Always check the medicine's label, which carries the schedule number inside a square border, or ask a pharmacist if you are unsure.

SAHPRA documents

Schedule verified from official documents

Schedule Verification

Kavideza, Viatris Healthcare (Pty) Ltd is scheduled S4 in its official SAHPRA documents, read with 90% confidence.

Professional information (PI)For healthcare professionalsKavideza, Viatris Healthcare (Pty) Ltd Patient information leaflet (PIL)For patients and carersKavideza, Viatris Healthcare (Pty) Ltd

These documents are provided by SAHPRA for informational purposes. Always consult with a healthcare professional for medical advice.

Research articles

Loading PubMed articles

Background